As respiratory syncytial virus (RSV), a seasonal pathogen in young children is challenging the national health care system as part of an unprecedented “tripledemic” with COVID-19 and flu this winter, authors with Leavitt Partners parent company Health Management Associates weigh in on potential coverage pathways for new monoclonal antibody (mAb) preventive therapies for RSV and … Read more